Restart Life Sciences Corp.
HEAL
CNSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.21% | 82.14% | |||
| Depreciation & Amortization | 866.67% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 44.54% | 81.79% | |||
| Operating Income | -0.90% | -81.79% | |||
| Income Before Tax | -107.89% | 26.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -107.89% | 26.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -107.89% | 26.37% | |||
| EBIT | -0.90% | -81.79% | |||
| EBITDA | -0.59% | -82.14% | |||
| EPS Basic | -41.38% | 32.56% | |||
| Normalized Basic EPS | 30.56% | -71.43% | |||
| EPS Diluted | -148.28% | 60.27% | |||
| Normalized Diluted EPS | 30.56% | -71.43% | |||
| Average Basic Shares Outstanding | 43.85% | 9.47% | |||
| Average Diluted Shares Outstanding | 43.85% | 9.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||